EISSN 2148-5607

TJG IS INDEXED IN SCI-EXPANDED AND PUBMED IMPACT FACTOR: 1.4

Turkish Journal of Gastroenterology

35 414 2024

HIGHLY CITED ARTICLES

HBV and HCV are the risk factors in CCA

Tan et al.

Serum resolvin levels in irritable bowel syndrome

Karatay and Gül Utku

Microbial improvement after intervention

Qian et al.

18F-FDGPET/CT in gallbladder carcinoma

Arslan et al.

Bezoar in endoscopy

Gökbulut et al.

Effect of vitamin D on CD40L gene expression in UC

Sharifi et al.

ERCP for acute cholangitis

Khamaysi and Taha

Inborn metabolic causes of fatty liver disease

Yıldız and Sivri

Gastric and small intestinal TSA

Kiremitci et al.

COVID-19 in Hepatology and Liver transplantation

Kabaçam et al.

Submission to First Decision = 31 Days

Original Articles

Metabolic Dysfunction-Associated Fatty Liver Disease and Fibrosis Status in Patients with Type 2 Diabetes Treated at Internal Medicine Clinics: Türkiye DAHUDER Awareness of Fatty Liver Disease (TR-DAFLD) Study

Yasin Şahintürk ¹ , Gökhan Köker ¹ , Nizameddin Koca ² , Hilmi Erdem Sümbül ³ , İsmail Demir ⁴ , Havva Keskin ⁵ , Selçuk Yaylacı ⁶ , İhsan Solmaz ⁷ , Banu Açmaz ⁸ , Hamit Yıldız ⁹ , Sibel Ocak Serin ¹⁰ , Şükriye Taşçı ¹¹ , Teslime Ayaz ¹² , Eşref Araç ¹³ , Hasan Sözel ¹⁴ , Ali Kırık ¹⁵ , Attila Önmez ¹⁶ , Seher Kır ¹⁷ , Hacer Şen ¹⁵ , Alihan Oral ¹⁸ , Fatih Necip Arıcı ³ , Mustafa Kanat ¹⁹ , Ayhan Hilmi Çekin ²⁰ , Seyit Uyar ¹

Author Affiliation(s)

1.

Department of Internal Medicine, University of Health Sciences Antalya Training and Research Hospital, Antalya, Türkiye

2.

Department of Internal Medicine, Bursa City Hospital, Bursa, Türkiye

3.

Department of Internal Medicine, Adana City Hospital, Adana, Türkiye

4.

Department of Internal Medicine, University of Health Sciences Bozyaka Training and Research Hospital, İzmir, Türkiye

5.

Department of Internal Medicine, Ankara University Faculty of Medicine, Ankara, Türkiye

6.

Department of Internal Medicine, Sakarya University Faculty of Medicine, Sakarya, Türkiye

7.

Department of Internal Medicine, University of Health Sciences Diyarbakır Gazi Yaşargil Training and Research Hospital, Diyarbakır, Türkiye

8.

Department of Internal Medicine, Kayseri City Hospital, Kayseri, Türkiye

9.

Department of Internal Medicine, Gaziantep University Faculty of Medicine, Gaziantep, Türkiye

10.

Department of Internal Medicine, University of Health Sciences Ümraniye Training and Research Hospital, İstanbul, Türkiye

11.

Department of Internal Medicine, Karadeniz Technical University Faculty of Medicine, Trabzon, Türkiye

12.

Department of Internal Medicine, Rize University Faculty of Medicine, Rize, Türkiye

13.

Department of Internal Medicine, Dicle University Faculty of Medicine, Diyarbakır, Türkiye

14.

Department of Internal Medicine, Akdeniz University Faculty of Medicine, Antalya, Türkiye

15.

Department of Internal Medicine, Balıkesir University Faculty of Medicine, Balıkesir, Türkiye

16.

Department of Internal Medicine, Düzce University Faculty of Medicine, Düzce, Türkiye

17.

Department of Internal Medicine, Ondokuz Mayıs University Faculty of Medicine, Samsun, Türkiye

18.

Department of Internal Medicine, Biruni University Faculty of Medicine, İstanbul, Türkiye

19.

Department of Internal Medicine, İstanbul Medeniyet University Faculty of Medicine, İstanbul, Türkiye

20.

Department of Gastroenterology, University of Health Sciences Antalya Training and Research Hospital, Antalya, Türkiye

Turk J Gastroenterol 2024; 35: 643-650

DOI: 10.5152/tjg.2024.24045

Keywords : Type 2 diabetes, metabolic dysfunction-associated fatty liver disease, ultrasound imaging, fibrosis index, awareness, MASLD

Read: 808 Downloads: 462 Published: 06 June 2024

Volume 35, Issue 8, August 2024

Previous Article

Background/Aims: This awareness study aimed to determine the ultrasound (US) examination rates in relation to US-confirmed metabolic dysfunction-associated fatty liver disease (MAFLD) diagnosis in internal medicine outpatients with type 2 diabetes (T2D) across Türkiye.

Materials and Methods: A total of 6283 T2D patients were included in this multicenter retrospective cohort study conducted at 17 internal medicine clinics across Türkiye. The presence and indications for US performed within the last 3 years were recorded along with US-confirmed MAFLD rates, laboratory findings on the day of US, and referral rates. Fibrosis-4 (FIB-4) index was calculated to estimate the risk of advanced liver fibrosis (FIB-4 index ≥ 1.3).

Results: Overall, 1731 (27.6%) of 6283 patients had US examination, which revealed MAFLD diagnosis in 69.9% of cases. In addition, 24.4% of patients with US-confirmed MAFLD were at risk of advanced fibrosis (FIB-4 index ≥ 1.3), and the referral rate was 15.5%.

Conclusion: In conclusion, our findings emphasize an insufficient MAFLD awareness among clinicians and the likelihood of most of T2D patients to be at risk of living with an unknown status regarding their MAFLD and advanced fibrosis risk.

Cite this article as: Şahintürk Y, Köker G, Koca N, et al. Metabolic dysfunction-associated fatty liver disease and fibrosis status in patients with type 2 diabetes treated at internal medicine clinics: Türkiye DAHUDER awareness of fatty liver disease (TR-DAFLD) study. Turk J Gastroenterol. 2024;35(8):643-650.

Files